Brucella Set

$1.00

WhatsApp Order

A Brucella Set is a comprehensive serological test system (Class II medical device, CE-marked/FDA-cleared) for qualitative and quantitative detection of antibodies against Brucella species (B. abortus, B. melitensis, B. suis, B. canis) using multiple methodologies including tube agglutination, slide agglutination, and 2-mercaptoethanol (2-ME) testing. The set includes killed, stained Brucella antigens, positive and negative controls, dilution tubes, reaction cards, and 2-ME reagent for IgM/IgG differentiation. Diagnostic titer ≥1:160 or fourfold rise confirms brucellosis. Primary clinical applications include diagnosis of brucellosis in endemic regions (undulant fever, night sweats, arthralgia), fever of unknown origin investigation, occupational health screening in high-risk workers (veterinarians, farmers, slaughterhouse workers), diagnosis of focal complications (sacroiliitis, spondylitis, meningitis, endocarditis), treatment monitoring (fourfold decline indicates response), outbreak investigation, and public health surveillance. Critical safety precautions include handling all samples in biosafety cabinet (Brucella is highly infectious via aerosol), 2-ME reagent toxicity (use fume hood), awareness of prozone phenomenon (serial dilutions essential), cross-reactions with other Gram-negative bacteria, and mandatory reporting to public health authorities. Essential test for brucellosis diagnosis in endemic regions and occupational health settings.

Categories: DIAGNOSTIC EQUIPMENT, Diagnostic Kits, Lab Consumables, LABORATORY EQUIPMENT AND SUPPLIES Tags: Brucella Test, Brucellosis, Febrile Antigens, Serology, Tube Agglutination, Undulant Fever, Zoonotic Disease

Description

Brucella Set

PRIMARY CLINICAL & DIAGNOSTIC USES

1. Diagnosis of Brucellosis in Endemic Regions:

Primary Use: Used for serological detection of antibodies against Brucella species (B. abortus, B. melitensis, B. suis, B. canis) in patients presenting with undulant fever, night sweats, arthralgia, fatigue, and other symptoms suggestive of brucellosis, particularly in endemic areas such as the Mediterranean basin, Middle East, Central Asia, and Latin America.
How it helps: Enables rapid, accurate diagnosis of a potentially debilitating infection that might otherwise be missed, allowing patients to receive appropriate antibiotic treatment before the disease progresses to chronic complications.

2. Fever of Unknown Origin Investigation:

Primary Use: Brucella testing is essential in the diagnostic workup of patients with prolonged fever of unknown origin, especially those with epidemiological risk factors such as consumption of unpasteurized dairy products, occupational exposure (farmers, veterinarians, slaughterhouse workers), or travel to endemic regions.
How it helps: Provides a definitive answer for patients suffering from persistent, unexplained fever, ending the frustration of months of uncertainty and guiding them toward effective treatment.

3. Occupational Health Screening in High-Risk Workers:

Primary Use: Used for regular screening of veterinarians, livestock handlers, slaughterhouse workers, and laboratory personnel who are at increased risk of occupational exposure to Brucella, enabling early detection and treatment.
How it helps: Protects the health of workers in high-risk professions by catching infections early, often before symptoms become severe, and preventing the spread of disease to families and communities.

4. Diagnosis of Complications (Osteoarticular, Neurological, Cardiovascular):

Primary Use: Brucella can cause focal complications including sacroiliitis, spondylitis, meningitis, endocarditis, and orchitis. Serological testing helps establish the etiology in patients presenting with these complications, particularly in endemic areas.
How it helps: Solves the mystery of seemingly unrelated severe complications—like joint pain, heart inflammation, or neurological symptoms—by revealing the underlying brucella infection, allowing for targeted treatment that addresses the root cause.

5. Treatment Monitoring and Follow-Up:

Primary Use: Serial antibody titers are used to monitor response to antibiotic therapy (doxycycline + rifampin or streptomycin). A fourfold decline in titers over 3-6 months indicates adequate treatment response, while persistent or rising titers suggest treatment failure or relapse.
How it helps: Takes the guesswork out of treatment, giving doctors and patients clear evidence of whether the infection is responding to antibiotics or if a different approach is needed to prevent relapse.

6. Screening in Blood and Tissue Donors:

Primary Use: In some endemic regions, screening of blood and tissue donors for Brucella antibodies may be performed to prevent transfusion-transmitted or transplant-transmitted brucellosis.
How it helps: Protects vulnerable patients who receive blood transfusions or organ transplants from acquiring a dangerous infection through donated materials, making the blood supply safer for everyone.

7. Outbreak Investigation and Public Health Surveillance:

Primary Use: Used during suspected outbreaks of brucellosis to identify cases, determine the source of infection (often contaminated dairy products), and implement control measures to prevent further transmission.
How it helps: Enables public health officials to quickly identify and contain outbreaks, protecting entire communities from further exposure and identifying contaminated food sources before they affect more people.

SECONDARY & SUPPORTIVE USES

1. Epidemiological Studies and Research: Used in population-based studies to determine prevalence, incidence, and risk factors for brucellosis in various populations and geographic regions, guiding public health policy and resource allocation.

2. Veterinary Medicine and Animal Health: Adapted for screening livestock (cattle, goats, sheep, pigs) to detect infected animals and implement control programs for animal brucellosis, which has significant economic and public health implications.

3. Food Safety Investigations: Used in investigations of foodborne outbreaks linked to unpasteurized dairy products (cheese, milk) to confirm Brucella contamination, helping remove dangerous products from the market.

4. Immigrant and Refugee Health Screening: May be used to screen individuals from endemic countries presenting with compatible symptoms or as part of comprehensive health assessments, ensuring new arrivals receive appropriate care.

5. Travel Medicine: Used to evaluate returning travelers from endemic areas with prolonged fever, arthralgia, or other symptoms suggestive of brucellosis, helping diagnose imported infections.

6. Differential Diagnosis of Rheumatic Symptoms: Brucella testing may be included in the workup of patients presenting with unexplained arthralgia, arthritis, or back pain in endemic areas, ruling out an infectious cause for joint symptoms.

7. Pre-Employment Screening for High-Risk Occupations: Some employers in high-risk industries may require baseline Brucella testing for new hires in occupational health programs, establishing a health baseline and protecting the workforce.

KEY PRODUCT FEATURES

1. BASIC IDENTIFICATION ATTRIBUTES

Test Type: Serological test for qualitative and quantitative detection of antibodies against Brucella species.
Common Names: Brucella Test, Brucella Antibody Test, Brucella Agglutination Test, Brucella Set, Febrile Antigen Set.
Methodologies Included in Set:
- Tube Agglutination Test (TAT): Standard method for quantitative antibody titration.
- Slide Agglutination Test (SAT): Rapid screening test for qualitative detection.
- 2-Mercaptoethanol (2-ME) Test: Distinguishes IgM (acute) from IgG (chronic) antibodies.
- Complement Fixation Test (CFT): Reference method for confirmation (in some sets).
Antigens Included:
- B. abortus antigen: For detection of antibodies to B. abortus.
- B. melitensis antigen: For detection of antibodies to B. melitensis (most common).
- B. suis antigen: For detection of antibodies to B. suis (some sets).
- B. canis antigen: For detection of antibodies to B. canis (some sets).
Sample Type: Serum (venous blood).
Test Time:
- Slide Agglutination: 2-5 minutes.
- Tube Agglutination: 24-48 hours (overnight incubation).
- 2-ME Test: 24-48 hours.
Interpretation: Antibody titer reported as highest dilution showing agglutination (e.g., 1:40, 1:80, 1:160, 1:320, 1:640).

2. TECHNICAL & PERFORMANCE PROPERTIES

Sensitivity: 95-98% for acute brucellosis; lower in chronic or focal disease.
Specificity: 95-99% (false positives can occur in tularemia, yersiniosis, cholera vaccination, and cross-reacting Gram-negative bacteria).
Diagnostic Titer: ≥1:160 in a single sample or fourfold rise between acute and convalescent samples is considered diagnostic in endemic areas; ≥1:80 may be significant in non-endemic areas.
Antibody Kinetics: IgM appears within 1-2 weeks, peaks at 3-4 weeks; IgG appears later and persists in chronic infection.
2-ME Test: Reduction in titer with 2-ME indicates IgG predominance (chronic infection); resistance to 2-ME indicates IgM (acute infection).
Cross-Reactivity: With Yersinia enterocolitica O:9, Francisella tularensis, Vibrio cholerae, and certain Escherichia coli strains.
Prozone Phenomenon: High antibody concentrations may cause false-negative agglutination at low dilutions; serial dilutions essential.

3. PHYSICAL & OPERATIONAL PROPERTIES

Kit Components (Complete Brucella Set):
- Brucella Antigens: Killed, stained Brucella suspensions (B. abortus, B. melitensis, B. suis, B. canis) in individual vials.
- Positive Control Serum: Serum with known Brucella antibody titer.
- Negative Control Serum: Non-reactive serum.
- Dilution Tubes: Glass or plastic tubes for serial dilutions.
- Diluent: Buffered saline for sample dilution.
- Reaction Cards (Slide Test): Ceramic or glass rings for slide agglutination.
- Mixing Sticks: Disposable sticks for sample-antigen mixing.
- 2-Mercaptoethanol (2-ME) Reagent: For IgM/IgG differentiation.
- Package Insert: Detailed instructions and interpretation guidelines.
Packaging Sizes: 50-200 tests per kit (depending on methodology and number of antigens).
Storage Requirements: 2-8°C; do not freeze; protect from light.
Shelf Life: 12-24 months depending on manufacturer and antigen stability.

4. SAFETY & COMPLIANCE ATTRIBUTES

Regulatory Status: Class II medical device requiring FDA 510(k) clearance or CE marking for IVD use; WHO prequalified for some tests.
Quality Control: Must run positive and negative controls with each batch; calibration curves for quantitative methods.
Biohazard Precautions: All patient samples potentially infectious for Brucella (highly contagious via aerosol), HIV, hepatitis B/C, and other bloodborne pathogens.
Chemical Safety: 2-ME reagent is toxic and has strong odor; use in fume hood; avoid skin and eye contact.
Disposal: Used test materials disposed of as biohazardous waste; 2-ME disposed as hazardous chemical waste.
Reporting: Brucellosis is a reportable disease in most countries; positive results require notification to public health authorities.

5. STORAGE & HANDLING ATTRIBUTES

Storage Temperature: 2-8°C; do not freeze; protect from light.
Sample Handling: Serum stable 7 days at 2-8°C; longer storage requires freezing at -20°C (avoid repeated freeze-thaw).
Antigen Preparation: Mix gently before use; avoid foaming; bring to room temperature.
Test Preparation (Tube Agglutination):
1. Prepare serial dilutions of patient serum (1:20 to 1:1280 or higher).
2. Add equal volume of Brucella antigen.
3. Incubate at 37°C for 24-48 hours.
4. Read agglutination pattern; report highest dilution with visible agglutination.
Test Preparation (Slide Agglutination):

Place drops of serum and positive/negative controls on reaction card rings.
Add a drop of antigen; mix with a stick.
Rock card for 2-5 minutes; observe for agglutination.

Expiration: Never use reagents beyond expiration date; performance compromised.
Quality Control: Run controls with each batch; document results per laboratory protocol.

6. LABORATORY & CLINICAL APPLICATIONS

Primary Application: Serological diagnosis of brucellosis through detection of antibodies against Brucella species in patients with compatible clinical presentation and epidemiological risk factors.
Testing Indications:
- Undulant fever, night sweats, fatigue, arthralgia in endemic areas.
- Fever of unknown origin with risk factors (unpasteurized dairy, occupational exposure, travel).
- Occupational screening in high-risk workers (veterinarians, farmers, slaughterhouse workers).
- Suspected focal complications (sacroiliitis, spondylitis, meningitis, endocarditis).
- Treatment monitoring and relapse detection.
Interpretation:
- Negative (<1:80): No significant antibodies; brucellosis unlikely.
- Borderline (1:80-1:160): May indicate early infection, past infection, or cross-reaction; repeat in 2-4 weeks.
- Positive (≥1:160): Significant antibody titer; supports diagnosis of brucellosis.
- Fourfold Rise: Between acute and convalescent samples confirms recent infection.
- 2-ME Test: Resistant = IgM predominant (acute infection); sensitive = IgG predominant (chronic infection).
Limitations: Cross-reactions with other Gram-negative bacteria; prozone phenomenon; lower sensitivity in chronic or focal disease; requires clinical correlation.

SAFETY HANDLING PRECAUTIONS

1. SAFETY PRECAUTIONS

Biological Hazard: Brucella is highly infectious via aerosol; all samples must be handled in a biosafety cabinet (BSL-2/3).
Laboratory-Acquired Infections: Brucella is one of the most common laboratory-acquired infections; follow strict biosafety protocols.
Hand Hygiene: Wash hands thoroughly after handling specimens and reagents.
Quality Control: Always run positive and negative controls with each batch.
2-ME Safety: Use in fume hood; avoid inhalation, skin contact, and eye contact.
Prozone Awareness: Always test serial dilutions; false negatives at low dilutions possible.
Clinical Correlation: Serology must be interpreted with clinical presentation and culture results when available.
Reporting: Positive results must be reported to public health authorities.
Storage Compliance: Store reagents at recommended temperature; degradation affects accuracy.

2. FIRST AID MEASURES

Needlestick/Sharps Injury: If injury occurs, wash area vigorously with soap and water; report immediately; follow institutional post-exposure prophylaxis protocol (doxycycline prophylaxis may be considered).
Blood Spill: Contain with absorbent material; disinfect area with 10% bleach solution; dispose as biohazard waste.
2-ME Contact (Skin): Wash affected area thoroughly with soap and water; remove contaminated clothing.
2-ME Contact (Eyes): Flush eyes with copious water for 15 minutes; seek medical attention.
2-ME Inhalation: Move to fresh air; seek medical attention if respiratory symptoms develop.
2-ME Ingestion: Contact poison control center; do not induce vomiting unless instructed.

3. FIRE FIGHTING MEASURES

Flammability: Liquid reagents contain preservatives; 2-ME is flammable; plastic components combustible.
Extinguishing Media: Use water, foam, CO₂, or dry chemical as appropriate.
Special Hazards: 2-ME is toxic and flammable; use appropriate PPE and SCBA in enclosed spaces.

Brucella Set

Brucella Set

PRIMARY CLINICAL & DIAGNOSTIC USES

1. Diagnosis of Brucellosis in Endemic Regions:

How it helps: Enables rapid, accurate diagnosis of a potentially debilitating infection that might otherwise be missed, allowing patients to receive appropriate antibiotic treatment before the disease progresses to chronic complications.

2. Fever of Unknown Origin Investigation:

How it helps: Provides a definitive answer for patients suffering from persistent, unexplained fever, ending the frustration of months of uncertainty and guiding them toward effective treatment.

3. Occupational Health Screening in High-Risk Workers:

Primary Use: Used for regular screening of veterinarians, livestock handlers, slaughterhouse workers, and laboratory personnel who are at increased risk of occupational exposure to Brucella, enabling early detection and treatment.

How it helps: Protects the health of workers in high-risk professions by catching infections early, often before symptoms become severe, and preventing the spread of disease to families and communities.

4. Diagnosis of Complications (Osteoarticular, Neurological, Cardiovascular):

Primary Use: Brucella can cause focal complications including sacroiliitis, spondylitis, meningitis, endocarditis, and orchitis. Serological testing helps establish the etiology in patients presenting with these complications, particularly in endemic areas.

How it helps: Solves the mystery of seemingly unrelated severe complications—like joint pain, heart inflammation, or neurological symptoms—by revealing the underlying brucella infection, allowing for targeted treatment that addresses the root cause.

5. Treatment Monitoring and Follow-Up:

Primary Use: Serial antibody titers are used to monitor response to antibiotic therapy (doxycycline + rifampin or streptomycin). A fourfold decline in titers over 3-6 months indicates adequate treatment response, while persistent or rising titers suggest treatment failure or relapse.

How it helps: Takes the guesswork out of treatment, giving doctors and patients clear evidence of whether the infection is responding to antibiotics or if a different approach is needed to prevent relapse.

6. Screening in Blood and Tissue Donors:

Primary Use: In some endemic regions, screening of blood and tissue donors for Brucella antibodies may be performed to prevent transfusion-transmitted or transplant-transmitted brucellosis.

How it helps: Protects vulnerable patients who receive blood transfusions or organ transplants from acquiring a dangerous infection through donated materials, making the blood supply safer for everyone.

7. Outbreak Investigation and Public Health Surveillance:

Primary Use: Used during suspected outbreaks of brucellosis to identify cases, determine the source of infection (often contaminated dairy products), and implement control measures to prevent further transmission.

How it helps: Enables public health officials to quickly identify and contain outbreaks, protecting entire communities from further exposure and identifying contaminated food sources before they affect more people.

SECONDARY & SUPPORTIVE USES

1. Epidemiological Studies and Research: Used in population-based studies to determine prevalence, incidence, and risk factors for brucellosis in various populations and geographic regions, guiding public health policy and resource allocation.

2. Veterinary Medicine and Animal Health: Adapted for screening livestock (cattle, goats, sheep, pigs) to detect infected animals and implement control programs for animal brucellosis, which has significant economic and public health implications.

3. Food Safety Investigations: Used in investigations of foodborne outbreaks linked to unpasteurized dairy products (cheese, milk) to confirm Brucella contamination, helping remove dangerous products from the market.

4. Immigrant and Refugee Health Screening: May be used to screen individuals from endemic countries presenting with compatible symptoms or as part of comprehensive health assessments, ensuring new arrivals receive appropriate care.

5. Travel Medicine: Used to evaluate returning travelers from endemic areas with prolonged fever, arthralgia, or other symptoms suggestive of brucellosis, helping diagnose imported infections.

6. Differential Diagnosis of Rheumatic Symptoms: Brucella testing may be included in the workup of patients presenting with unexplained arthralgia, arthritis, or back pain in endemic areas, ruling out an infectious cause for joint symptoms.

7. Pre-Employment Screening for High-Risk Occupations: Some employers in high-risk industries may require baseline Brucella testing for new hires in occupational health programs, establishing a health baseline and protecting the workforce.

1. BASIC IDENTIFICATION ATTRIBUTES

Test Type: Serological test for qualitative and quantitative detection of antibodies against Brucella species.

Common Names: Brucella Test, Brucella Antibody Test, Brucella Agglutination Test, Brucella Set, Febrile Antigen Set.

Methodologies Included in Set:

Tube Agglutination Test (TAT): Standard method for quantitative antibody titration.

Slide Agglutination Test (SAT): Rapid screening test for qualitative detection.

2-Mercaptoethanol (2-ME) Test: Distinguishes IgM (acute) from IgG (chronic) antibodies.

Complement Fixation Test (CFT): Reference method for confirmation (in some sets).

Antigens Included:

B. abortus antigen: For detection of antibodies to B. abortus.

B. melitensis antigen: For detection of antibodies to B. melitensis (most common).

B. suis antigen: For detection of antibodies to B. suis (some sets).

B. canis antigen: For detection of antibodies to B. canis (some sets).

Sample Type: Serum (venous blood).

Test Time:

Slide Agglutination: 2-5 minutes.

Tube Agglutination: 24-48 hours (overnight incubation).

2-ME Test: 24-48 hours.

Interpretation: Antibody titer reported as highest dilution showing agglutination (e.g., 1:40, 1:80, 1:160, 1:320, 1:640).

2. TECHNICAL & PERFORMANCE PROPERTIES

Sensitivity: 95-98% for acute brucellosis; lower in chronic or focal disease.

Specificity: 95-99% (false positives can occur in tularemia, yersiniosis, cholera vaccination, and cross-reacting Gram-negative bacteria).

Diagnostic Titer: ≥1:160 in a single sample or fourfold rise between acute and convalescent samples is considered diagnostic in endemic areas; ≥1:80 may be significant in non-endemic areas.

Antibody Kinetics: IgM appears within 1-2 weeks, peaks at 3-4 weeks; IgG appears later and persists in chronic infection.

2-ME Test: Reduction in titer with 2-ME indicates IgG predominance (chronic infection); resistance to 2-ME indicates IgM (acute infection).

Cross-Reactivity: With Yersinia enterocolitica O:9, Francisella tularensis, Vibrio cholerae, and certain Escherichia coli strains.

Prozone Phenomenon: High antibody concentrations may cause false-negative agglutination at low dilutions; serial dilutions essential.

3. PHYSICAL & OPERATIONAL PROPERTIES

Kit Components (Complete Brucella Set):

Brucella Antigens: Killed, stained Brucella suspensions (B. abortus, B. melitensis, B. suis, B. canis) in individual vials.

Positive Control Serum: Serum with known Brucella antibody titer.

Negative Control Serum: Non-reactive serum.

Dilution Tubes: Glass or plastic tubes for serial dilutions.

Diluent: Buffered saline for sample dilution.

Reaction Cards (Slide Test): Ceramic or glass rings for slide agglutination.

Mixing Sticks: Disposable sticks for sample-antigen mixing.

2-Mercaptoethanol (2-ME) Reagent: For IgM/IgG differentiation.

Package Insert: Detailed instructions and interpretation guidelines.

Packaging Sizes: 50-200 tests per kit (depending on methodology and number of antigens).

Storage Requirements: 2-8°C; do not freeze; protect from light.

Shelf Life: 12-24 months depending on manufacturer and antigen stability.

4. SAFETY & COMPLIANCE ATTRIBUTES

Regulatory Status: Class II medical device requiring FDA 510(k) clearance or CE marking for IVD use; WHO prequalified for some tests.

Quality Control: Must run positive and negative controls with each batch; calibration curves for quantitative methods.

Biohazard Precautions: All patient samples potentially infectious for Brucella (highly contagious via aerosol), HIV, hepatitis B/C, and other bloodborne pathogens.

Chemical Safety: 2-ME reagent is toxic and has strong odor; use in fume hood; avoid skin and eye contact.

Disposal: Used test materials disposed of as biohazardous waste; 2-ME disposed as hazardous chemical waste.

Reporting: Brucellosis is a reportable disease in most countries; positive results require notification to public health authorities.

5. STORAGE & HANDLING ATTRIBUTES

Storage Temperature: 2-8°C; do not freeze; protect from light.